SAN DIEGO, March 8, 2016 /PRNewswire/ -- NI Research has released the March-April issue of NeuroPerspective, featuring comprehensive reviews of Depression and of Autism.
Logo - http://photos.prnewswire.com/prnh/20160307/341407LOGO
“Perhaps surprisingly, this may be one of the most optimistic issues NIR has ever produced, despite the angst that has swept the world’s financial markets, roiled by intransigent conflicts, terrorist turbulence, and BizarroWorld politics; and where Biotech, a high-beta weathervane for winds from any direction, has seen valuations plummet,” said NeuroPerspective publisher Harry Tracy, PhD.
The reason is twofold:
“Depression is the therapeutic area where the prospects for meaningful transformations in the current Treatment Paradigm are most accessible and probable. We are in or approaching Phase III with multiple strategies for providing rapid relief of depression, in a context where ‘wait a few weeks’ has been the perennial post-script to every new prescription. By 2020, the treatment landscape for depression will be transformed, undoing the death grip that the generics have had on the prospects for drug development for Psychiatry. On a longer-term track, Autism is the example of a paradigm shift underway, not yet in terms of treatment, but in research methodology. The use of real-time biosensors, in concert with large-population genomics and biomarkers, puts Autism on the leading edge for the emergence of a research paradigm with both conceptual and predictive validity,” he said.
The Depression review includes assessments of programs from Janssen/JNJ, Allergan (from Naurex), Alkermes, Cerecor, and many others. Sidebars include assessments of the landscape in Post-Partum Depression, Suicidality, Bipolar Depression, and the ALKS 5461 pivotal program. The Autism review includes programs from Allergan/Rugen, Neuren, Roche, Simons Foundation, and numerous academic research institutions.
The March/April issue also provides company reviews for NeuroRx and Annexon Biosciences; commentary on the increased complexity now associated with the mHtt target in Huntington’s; the Complement C4a system in schizophrenia; and a consideration of the Pharma industry’s PR problems-'Why Do They Hate Us?’
About NI Research
NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. NeuroPerspective is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analyses of therapeutics-in-development.
A one-year (1-5 user) subscription to NeuroPerspective is $2525. Startup/academic pricing is available. The Depression/Autism review issue of NeuroPerspective is being offered as a single-issue purchase for $500.
NI Research also publishes NeuroLicensing, which comprehensively reviews current licensing trends in the CNS area, and assesses large and midsize pharma companies in terms of their licensing agendas and performance. In addition, NI Research provides consulting services to the pharma industry.
Further information and online purchasing with immediate download are available at http://www.niresearch.com/onlinestore.html.
Contact: NI Research, P.O. Box 1028, Cardiff CA 92007; 760-753-6376.
E-mail: info@niresearch.com
Contact:
Harry Tracy
NI Research
760-753-6376
Email
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/depression-and-autism-reviewed-by-neuroperspective-300232346.html
SOURCE NI Research
